Brigatinib Outperforms Crizotinib as First-Line Therapy. -

Brigatinib Outperforms Crizotinib as First-Line Therapy.

Abstract	The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in patients with untreated non-small cell lung cancer. Brigatinib yielded a longer progression-free survival, a higher objective response rate, and greater effectiveness against brain metastases-and was less detrimental to patients' quality of life.
Authors
Journal	Cancer discovery (Cancer Discov) Vol. 10 Issue 2 Pg. OF5 (02 2020) ISSN: 2159-8290 [Electronic] United States
PMID	31879274 (Publication Type: News)
Copyright	©2019 American Association for Cancer Research.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!